Previous Close | 0.1170 |
Open | 0.1290 |
Bid | 0.0000 x 1800 |
Ask | 0.0000 x 1300 |
Day's Range | 0.1050 - 0.1290 |
52 Week Range | 0.0510 - 0.3540 |
Volume | |
Avg. Volume | 19,595 |
Market Cap | 5.632M |
Beta (5Y Monthly) | 1.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0800 |
Earnings Date | Mar 29, 2024 - Apr 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder). This approval marks a significant milestone in Emmaus' mission to improve the lives of people with SCD around the world and provides access to this important therapy for the patients living with SCD in Puerto Rico. In addition, Endari® is approved in the United State
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.